Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

532586.pdf (204.96 KB)

Document type

Article

Version

Published version

Publication date

2004-12

All rights reserved

Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/55248

A mouse peritonitis model for the study of glycopeptide efficacy in GISA infections

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

http://dx.doi.org/10.1089/mdr.2004.10.346

Abstract

In recent years, the emergence of Staphylococcus aureus strains with reduced susceptibility to glycopeptides has raised considerable concern. We studied the efficacy of vancomycin and teicoplanin, as well as cloxacillin and cefotaxime, against the infection caused by four S. aureus strains with different glycopeptide and β-lactam susceptibilities (strains A, B, C, and D; MICs for vancomycin of 1, 2, 4, and 8 µg/ml respectively), using a modified model of mouse peritonitis. This optimized model appeared to be straightforward and reproducible, and was able to detect low differences in bacterial killing between antibiotics and also between different S. aureus strains. Bactericidal activities in peritoneal fluid for vancomycin, teicoplanin, cloxacillin, and cefotaxime decreased from -2.98, -2.36, -3.22, and -3.57 log10 cfu/ml, respectively, in infection by strain A (MICs for vancomycin and cloxacillin of 1 and 0.38 µg/ml, respectively) to -1.22, -0.65, -1.04, and +0.24 in peritonitis due to strain D (MICs for vancomycin and cloxacillin of 8 and 1,024 µg/ml). Our data confirm the superiority of β-lactams against methicillin-susceptible S. aureus and show that bactericidal activity of glycopeptides decreases significantly with slight increases in MICs; this finding suggests a reduced efficacy of glycopeptides in the treatment of serious glycopeptide-intermediate S. aureus infections

Subject

Infeccions per estafilococs, Antibiòtics, Ratolins (Animals de laboratori), Medicaments antibacterians, Resistència als medicaments, Peritonitis

Subject (English)

Staphylococcal infections, Antibiotics, Mice (Laboratory animals), Antibacterial agents, Drug resistance, Peritonitis

Citation

Collections

Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Patologia i Terapèutica Experimental)

Citation

DOMÉNECH ARIZA, Alejandro, et al. A mouse peritonitis model for the study of glycopeptide efficacy in GISA infections. Microbial Drug Resistance. 2004. Vol. 10, num. 4, pags. 346-353. ISSN 1076-6294. [consulted: 10 of August of 2026]. Available at: https://hdl.handle.net/2445/55248

Export metadata

JSON - METS

Share record